Eli Lilly's retatrutide, the first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has produced the largest weight-loss effect ever reported in a pivotal obesity trial. In TRIUMPH-1 (NCT05929066), the 12 mg dose achieved -28.3% body weight at 80 weeks — a mean loss of 70.3 pounds — with 45.3% of participants losing at least 30% of their body weight. The results were presented at the American Diabetes Association 86th Scientific Sessions on June 6, 2026, alongside the TRANSCEND-T2D-1 type 2 diabetes trial, which was simultaneously published in The Lancet.
Retatrutide activates three incretin and metabolic hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple mechanism is designed to go beyond the dual GIP/GLP-1 agonism of tirzepatide (Zepbound/Mounjaro) by adding glucagon receptor activation, which increases energy expenditure and has been shown in preclinical models to promote hepatic fat oxidation. If approved, retatrutide would be the first triple agonist to reach the US market.
TRIUMPH-1: the obesity pivotal
TRIUMPH-1 randomized 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes, to one of four arms: retatrutide 4 mg, 9 mg, 12 mg, or placebo. All participants received diet and exercise counseling. Dose escalation was gradual over 24 weeks to the target maintenance dose.
Weight loss at 80 weeks
| Arm | Body weight change | Pounds lost | ≥5% | ≥15% | ≥25% | ≥30% |
|---|---|---|---|---|---|---|
| Retatrutide 12 mg | -28.3% | -70.3 lbs | 98% | 85% | 52% | 45.3% |
| Retatrutide 9 mg | -25.9% | -64.4 lbs | 96% | 79% | 42% | 35.8% |
| Retatrutide 4 mg | -19.0% | -47.2 lbs | 90% | 60% | 21% | 15.5% |
| Placebo | -2.2% | -5.5 lbs | 24% | 6% | 1% | 0.6% |
Nearly all participants on the 12 mg dose (98%) achieved at least 5% weight loss. More than half (52%) lost at least 25% of their body weight. And 45.3% — nearly half — lost 30% or more. The 30% threshold matters because it represents a level of weight loss historically achievable only through bariatric surgery, and it is increasingly used by payers as a benchmark for "clinically meaningful" obesity treatment.
Cardiometabolic improvements
Retatrutide 12 mg also produced substantial improvements in cardiometabolic markers:
| Marker | Change from baseline |
|---|---|
| Triglycerides | -41.0% |
| Non-HDL cholesterol | -24.2% |
| Systolic blood pressure | -12.3 mmHg |
| Waist circumference | -24.1 cm |
| hsCRP (inflammation) | Reductions consistent with metabolic improvement |
These cardiometabolic benefits are clinically significant on their own. A 12.3 mmHg reduction in systolic blood pressure is comparable to a first-line antihypertensive. A 41% reduction in triglycerides exceeds what most patients achieve with statin monotherapy. Whether these improvements translate into cardiovascular outcome benefits is being tested in the ongoing TRANSCEND-Outcomes CVOT.
Nested basket: knee OA and sleep apnea
TRIUMPH-1 included nested assessments for obesity-related complications:
- Knee osteoarthritis: Up to 73% improvement in knee OA pain scores
- Obstructive sleep apnea: Up to 60% reduction in Apnea-Hypopnea Index (AHI)
These are not secondary endpoints in a separate trial — they are embedded assessments within the same patient population. If confirmed in dedicated Phase 3 programs, they position retatrutide as more than a weight-loss drug: a treatment for the metabolic complications of obesity.
104-week extension (BMI ≥35)
In a subgroup of participants with BMI ≥35 who continued treatment to 104 weeks, retatrutide 12 mg achieved -30.3% body weight — a mean loss of 85.0 pounds. This suggests continued weight loss beyond the primary 80-week endpoint, with no plateau observed through two years of treatment.
TRANSCEND-T2D-1: the diabetes pivotal
TRANSCEND-T2D-1 (NCT06354660) enrolled 537 adults with type 2 diabetes, mean baseline A1C of 7.9%, and mean diabetes duration of 2.5 years. All were inadequately controlled on diet and exercise alone.
Glycemic control and weight loss at 40 weeks
| Arm | A1C change | Weight change | A1C ≤6.5% | Normal blood sugar* |
|---|---|---|---|---|
| Retatrutide 12 mg | -1.9% | -15.3% | — | 46% |
| Retatrutide 9 mg | -1.9% | -13.9% | — | — |
| Retatrutide 4 mg | -1.7% | -11.5% | — | — |
| Placebo | -0.8% | -2.6% | — | — |
* "Normal blood sugar" defined as A1C <5.7% (below the prediabetes threshold).
The A1C reductions of -1.7% to -1.9% (treatment-regimen estimand) are among the largest reported for any GLP-1–based therapy in a diabetes pivotal trial; the efficacy estimand showed reductions of up to -2.0%. The 12 mg arm produced a -15.3% weight loss — remarkable for a diabetes population where weight loss is typically more modest than in non-diabetic obesity populations. Nearly half (46%) of participants on the 12 mg dose achieved normal blood sugar levels (A1C <5.7%), crossing below the prediabetes threshold entirely.
Up to 68% of retatrutide-treated participants achieved the composite endpoint of A1C ≤6.5% with ≥10% weight reduction — a combination that reflects both glycemic control and meaningful weight loss.
Safety: a new urinary tract infection signal
The gastrointestinal adverse event profile is consistent with the GLP-1 receptor agonist class: nausea, diarrhea, constipation, and vomiting, mostly mild to moderate, primarily during dose escalation. But two signals require attention.
Adverse events in TRIUMPH-1
| Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| URTI | 14.2% | 12.2% | 13.1% | 11.6% |
| Dysesthesia | 5.1% | 12.3% | 12.5% | 0.9% |
| Urinary tract infection | 7.5% | 8.8% | 8.4% | 5.3% |
| Discontinuation due to AE | 4.1% | 6.9% | 11.3% | 4.9% |
Adverse events in TRANSCEND-T2D-1
| Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 16.4% | 19.5% | 26.5% | 3.7% |
| Diarrhea | 18.7% | 26.3% | 22.8% | 4.5% |
| Vomiting | 15.7% | 15.0% | 17.6% | 2.2% |
| Dysesthesia | 4.5% | 2.3% | 4.4% | 0.0% |
| Urinary tract infection | 0.7% | 1.5% | 2.9% | 0.0% |
| Discontinuation due to AE | 2.2% | 4.5% | 5.1% | 0.0% |
The urinary tract infection signal is new and has not been seen with other incretin therapies. In TRIUMPH-1, UTI rates were 7.5–8.8% across retatrutide doses versus 5.3% with placebo — a modest absolute increase but a consistent signal. Lead investigator Dr. Ania Jastreboff (Yale) noted at ADA that UTIs occurred predominantly in women and may be related to hydration status, though the mechanism is not established. The TRANSCEND-T2D-1 signal was smaller (0.7–2.9% vs. 0% placebo) but directionally consistent.
The discontinuation rate due to adverse events is notable at the 12 mg dose: 11.3% in TRIUMPH-1 and 5.1% in TRANSCEND-T2D-1. This suggests that the dose-response curve for efficacy outpaces tolerability at the highest dose, a pattern that will inform the FDA's benefit-risk assessment and may result in a label that emphasizes gradual dose titration.
No hypoglycemia was reported in TRANSCEND-T2D-1, consistent with the glucose-dependent mechanism of incretin therapies.
What this means for the obesity market and payer strategy
1. The weight-loss ceiling has moved again. Tirzepatide (Zepbound) set the bar at approximately -22.5% in SURMOUNT-1. Retatrutide at 12 mg clears that bar by nearly 6 percentage points. This is not an incremental improvement — it is a clinically meaningful advancement that pushes the efficacy frontier closer to bariatric surgery. For payers, it means the GLP-1 market will continue to stratify by efficacy, and coverage criteria based on the "adequate trial" of existing therapies may need updating.
2. The NDA filing will set up a three-product Lilly franchise. Lilly already markets tirzepatide (Zepbound/Mounjaro) and orforglipron (Foundayo). Retatrutide would be the third incretin therapy in the Lilly portfolio, positioned as the highest-efficacy option for severe obesity and treatment-resistant patients. The key regulatory question is whether the FDA will view the 12 mg dose's 11.3% discontinuation rate as acceptable for a chronic obesity therapy, or whether the labeled maximum dose will be 9 mg.
3. The UTI signal needs post-marketing surveillance. A new adverse event signal not seen with other GLP-1 therapies will likely require a post-marketing requirement (PMR) study. Payers and formulary committees should expect a REMS or PMR commitment from Lilly as part of any approval. The signal's mechanism — whether it is drug-specific, class-related, or confounded by weight-loss–related physiological changes — will take years to clarify.
4. The nested knee OA and sleep apnea data are commercial differentiators. If Lilly pursues supplemental indications for these obesity complications, retatrutide could become the first incretin therapy with labeled efficacy for osteoarthritis pain and obstructive sleep apnea. These are massive underserved markets with no approved pharmacologic treatments. The commercial potential extends well beyond the obesity market into musculoskeletal and respiratory indications.
5. The CVOT will determine long-term access. The TRANSCEND-Outcomes cardiovascular outcomes trial is ongoing. Given the magnitude of cardiometabolic improvements seen in TRIUMPH-1 (triglycerides -41%, systolic BP -12.3 mmHg), there is a plausible case for cardiovascular benefit. If TRANSCEND-Outcomes is positive, retatrutide would join semaglutide (SELECT) and tirzepatide (SURMOUNT-MMO) as incretin therapies with proven cardiovascular outcomes — a class effect that would transform payer coverage from "weight-loss benefit" to "cardiovascular risk reduction."
Sources
- Eli Lilly and Company, "Lilly's Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial," press release, May 21, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- Eli Lilly and Company, "Lilly's Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Body Weight in Pivotal Phase 3 TRANSCEND-T2D-1 Trial," press release, March 19, 2026. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
- Eli Lilly and Company, "Lilly's Triple Agonist, Retatrutide, Drove Substantial Improvements in Weight, A1C, Knee OA Pain, and OSA at ADA 2026," press release, June 6, 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteoarthritis-pain-and-obstructive-sleep-apnea-demonstrating-its-remarkable-potential-to-treat-obesity-and-its-complications-302793169.html
- Jastreboff AM, et al. "Retatrutide in Adults with Type 2 Diabetes: The TRANSCEND-T2D-1 Phase 3 Trial." The Lancet, published online June 6, 2026.
- ClinicalTrials.gov. NCT05929066 (TRIUMPH-1) and NCT06354660 (TRANSCEND-T2D-1). https://clinicaltrials.gov
- Medscape, "Retatrutide Data Show Dramatic Weight Loss, Other Benefits at ADA 2026." https://www.medscape.com/viewarticle/retatrutide-data-show-dramatic-weight-loss-other-benefits-2026a1000iz0
- ADA Meeting News, "Triple-Hormone Therapy Demonstrates Efficacy for Type 2 Diabetes and Obesity." https://www.adameetingnews.org/triple-hormone-therapy-demonstrates-efficacy-for-type-2-diabetes-and-obesity
